Gilead Builds Japan Oncology Presence With Trodelvy

Yescarta Also Back In House

 
• By Lisa Takagi

Gilead aims to launch its key oncology product Trodelvy by 2024 in Japan while building a dedicated business unit for oncology in the firm’s Japanese office. The firm has expanded its exclusive rights for oncology products in APAC.

Gilead aims to launch Trodelvy in Japan in 2024, where its Phase III for TNBC and lung cancer has been ongoing .
Gilead aims to launch Trodelvy in Japan in 2024, where its Phase III for TNBC and lung cancer has been ongoing. • Source: Shutterstock

More from Japan

More from Focus On Asia